vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Strawberry Fields REIT, Inc. (STRW). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $40.1M, roughly 1.9× Strawberry Fields REIT, Inc.). Strawberry Fields REIT, Inc. runs the higher net margin — 5.0% vs -9.6%, a 14.6% gap on every dollar of revenue. On growth, Strawberry Fields REIT, Inc. posted the faster year-over-year revenue change (31.5% vs -16.8%). Over the past eight quarters, Strawberry Fields REIT, Inc.'s revenue compounded faster (20.0% CAGR vs -8.4%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Strawberry Fields REIT, Inc. is a real estate investment trust focused on healthcare-related real estate assets. It owns, operates and manages skilled nursing facilities, senior living communities, and medical office buildings, primarily serving markets across the United States for healthcare providers and elderly care operators.

BIOX vs STRW — Head-to-Head

Bigger by revenue
BIOX
BIOX
1.9× larger
BIOX
$77.6M
$40.1M
STRW
Growing faster (revenue YoY)
STRW
STRW
+48.3% gap
STRW
31.5%
-16.8%
BIOX
Higher net margin
STRW
STRW
14.6% more per $
STRW
5.0%
-9.6%
BIOX
Faster 2-yr revenue CAGR
STRW
STRW
Annualised
STRW
20.0%
-8.4%
BIOX

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
BIOX
BIOX
STRW
STRW
Revenue
$77.6M
$40.1M
Net Profit
$-7.4M
$2.0M
Gross Margin
46.8%
Operating Margin
9.3%
52.4%
Net Margin
-9.6%
5.0%
Revenue YoY
-16.8%
31.5%
Net Profit YoY
-20.2%
37.6%
EPS (diluted)
$-0.12
$0.15

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
STRW
STRW
Q4 25
$40.1M
Q3 25
$77.6M
$39.7M
Q2 25
$37.9M
Q1 25
$60.6M
$37.3M
Q4 24
$98.8M
$30.5M
Q3 24
$93.3M
$29.5M
Q2 24
$29.3M
Q1 24
$84.0M
$27.8M
Net Profit
BIOX
BIOX
STRW
STRW
Q4 25
$2.0M
Q3 25
$-7.4M
$2.0M
Q2 25
$2.0M
Q1 25
$-1.6M
$1.6M
Q4 24
$605.2K
$1.5M
Q3 24
$-6.2M
$944.0K
Q2 24
$938.0K
Q1 24
$9.8M
$746.0K
Gross Margin
BIOX
BIOX
STRW
STRW
Q4 25
Q3 25
46.8%
Q2 25
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
Q1 24
50.8%
Operating Margin
BIOX
BIOX
STRW
STRW
Q4 25
52.4%
Q3 25
9.3%
56.6%
Q2 25
54.5%
Q1 25
1.5%
54.1%
Q4 24
14.5%
51.5%
Q3 24
2.5%
54.4%
Q2 24
52.3%
Q1 24
15.7%
51.3%
Net Margin
BIOX
BIOX
STRW
STRW
Q4 25
5.0%
Q3 25
-9.6%
5.1%
Q2 25
5.2%
Q1 25
-2.6%
4.2%
Q4 24
0.6%
4.8%
Q3 24
-6.6%
3.2%
Q2 24
3.2%
Q1 24
11.6%
2.7%
EPS (diluted)
BIOX
BIOX
STRW
STRW
Q4 25
$0.15
Q3 25
$-0.12
$0.16
Q2 25
$0.16
Q1 25
$-0.02
$0.13
Q4 24
$0.00
$0.17
Q3 24
$-0.10
$0.14
Q2 24
$0.14
Q1 24
$0.14
$0.12

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
STRW
STRW
Cash + ST InvestmentsLiquidity on hand
$15.5M
$31.8M
Total DebtLower is stronger
$794.7M
Stockholders' EquityBook value
$288.3M
$12.1M
Total Assets
$734.9M
$885.2M
Debt / EquityLower = less leverage
65.64×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
STRW
STRW
Q4 25
$31.8M
Q3 25
$15.5M
$19.8M
Q2 25
$96.3M
Q1 25
$38.5M
$42.3M
Q4 24
$29.2M
$48.4M
Q3 24
$32.3M
$29.3M
Q2 24
$16.1M
Q1 24
$16.4M
$15.1M
Total Debt
BIOX
BIOX
STRW
STRW
Q4 25
$794.7M
Q3 25
$779.4M
Q2 25
$794.1M
Q1 25
$715.5M
Q4 24
$673.9M
Q3 24
$584.5M
Q2 24
$555.0M
Q1 24
$560.4M
Stockholders' Equity
BIOX
BIOX
STRW
STRW
Q4 25
$12.1M
Q3 25
$288.3M
$14.2M
Q2 25
$15.5M
Q1 25
$345.0M
$19.6M
Q4 24
$346.3M
$18.2M
Q3 24
$346.0M
$12.6M
Q2 24
$7.4M
Q1 24
$348.5M
$7.5M
Total Assets
BIOX
BIOX
STRW
STRW
Q4 25
$885.2M
Q3 25
$734.9M
$880.6M
Q2 25
$897.3M
Q1 25
$798.2M
$834.8M
Q4 24
$835.2M
$787.6M
Q3 24
$827.3M
$661.5M
Q2 24
$635.9M
Q1 24
$836.1M
$634.9M
Debt / Equity
BIOX
BIOX
STRW
STRW
Q4 25
65.64×
Q3 25
54.70×
Q2 25
51.26×
Q1 25
36.47×
Q4 24
37.09×
Q3 24
46.34×
Q2 24
74.61×
Q1 24
74.81×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
STRW
STRW
Operating Cash FlowLast quarter
$14.4M
$90.0M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
44.62×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
STRW
STRW
Q4 25
$90.0M
Q3 25
$14.4M
$20.7M
Q2 25
$29.8M
Q1 25
$23.3M
$19.0M
Q4 24
$-5.4M
$59.3M
Q3 24
$5.2M
$11.8M
Q2 24
$20.6M
Q1 24
$-17.4M
$2.1M
Cash Conversion
BIOX
BIOX
STRW
STRW
Q4 25
44.62×
Q3 25
10.26×
Q2 25
15.24×
Q1 25
11.97×
Q4 24
-8.85×
40.44×
Q3 24
12.53×
Q2 24
21.93×
Q1 24
-1.78×
2.85×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons